UPDATE: Morgan Stanley Upgrades Affymetrix; Removes PT

According to a research report published this morning, Morgan Stanley has upgraded Affymetrix AFFX from Underweight to Equal-weight, and removed its $4 PT. Morgan Stanley commented in the report, "We are upgrading our rating to EW as a result of the company's amended agreement to acquire eBioscience, a deal which should improve the long-term profitability, growth and stability of AFFX." Affymetrix is currently trading at $4.91.